Table 4.
Serological profile and follow-up of HCW with NSSIs
| Characteristics | Frequency | % | |
|---|---|---|---|
| HBV vaccination status (n=78) | Completed | 42 | 53.8 |
| Incomplete | 15 | 19.2 | |
| No | 09 | 11.5 | |
| Unknown | 12 | 15.4 | |
| Anti-HBs Titre (n=78) | Positive | 05 | 06.4 |
| Negative | 13 | 16.7 | |
| Screening not done/History not Provided | 60 | 76.9 | |
| Post-exposure management (n=78) | Post-injury Hep B vaccination | 28 | 35.9 |
| Post-injury Hep B HBIG | 00 | 00.0 | |
| Tetanus Toxoid (TT) | 78 | 100 | |
| Status of Source/patient (HBV/HIV/HCV/VDRL) screened (n=78) | HBsAg and HCV reactive | 01 | 01.3 |
| HBsAg reactive | 07 | 09.0 | |
| Anti-HCV reactive | 07 | 09.0 | |
| Anti-HIV reactive | 12 | 15.4 | |
| Not done/unknown | 26 | 33.3 | |
| VDRL reactive | 01 | 01.3 | |
| Negative for HBV/HCV/VDRL/HIV | 24 | 30.8 | |
| Status of HCW at time of NSSI (HBV/HIV/HCV) (n=78) | Negative | 78 | 100 |
| Positive | 00 | 0.00 | |
| Post-exposure prophylaxis for HIV (n=50) | Indicated* | 38 | 76.0 |
| Incomplete | 02 | 04.0 | |
| Completed PEP (28 Days) | 10 | 20.0 |
*Indicated includes 12 Anti-HIV reactive + 2sources unknown